Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898092602> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2898092602 endingPage "S863" @default.
- W2898092602 startingPage "S863" @default.
- W2898092602 abstract "A standard of care for resectable early-stage non-small cell lung cancer (NSCLC) is surgery alone or in combination with adjuvant or neoadjuvant platinum-based doublet chemotherapy (PT-DC). Nevertheless, 30%-70% of patients develop recurrence and die due to disease progression, highlighting the unmet need for more efficacious treatment regimens. Atezolizumab, an anti–programmed death-ligand 1 (anti–PD-L1) antibody that reinvigorates the anti-cancer immune response, has shown efficacy as monotherapy and in combination with chemotherapy in advanced NSCLC. On the basis of this activity, it is thought that the combination of atezolizumab and PT-DC may provide clinical benefit in the neoadjuvant setting by enhancing cancer cell killing and eradicating micro-metastases prior to surgery, thereby reducing the risk of disease recurrence. The objective of IMpower030 (NCT03456063) is to evaluate the efficacy and safety of atezolizumab in combination with PT-DC as neoadjuvant treatment for patients with resectable early-stage NSCLC. IMpower030 is a global, Phase III, multicenter, double-blind, randomized study in patients with histologically or cytologically confirmed, resectable stage II, IIIA, or select IIIB (T3N2) NSCLC (per AJCC/UICC, 8th ed). Study inclusion requires measurable disease per RECIST v1.1, ECOG PS of 0/1, and eligibility for R0 resection with curative intent and PT-DC. Patients who have received prior therapy for lung cancer or who present with non-squamous NSCLC with activating EGFR mutations or ALK translocation are excluded. Approximately 302 patients will be randomized to receive 4 cycles of neoadjuvant atezolizumab (1200 mg Q3W, Arm A) or placebo (Arm B) in combination with an investigator-selected PT-DC regimen. Following surgical resection and pathology response assessment, treatment assignment will be unblinded; patients in Arm A will receive adjuvant treatment with atezolizumab for up to 16 cycles or until disease recurrence or unacceptable toxicity, whereas patients in Arm B will receive best supportive care and scheduled observational follow-up. The primary efficacy endpoint is major pathological response, defined as ≤ 10% residual viable tumor tissue at time of resection as assessed by an independent central pathology laboratory. Secondary efficacy endpoints include OS, ORR, investigator-assessed event-free survival and disease-free survival per RECIST v1.1, pathological complete response and patient-reported outcomes. Exploratory biomarkers will also be evaluated. Section not applicable Section not applicable" @default.
- W2898092602 created "2018-11-02" @default.
- W2898092602 creator A5004849412 @default.
- W2898092602 creator A5026731588 @default.
- W2898092602 creator A5032753570 @default.
- W2898092602 creator A5036091074 @default.
- W2898092602 creator A5037979055 @default.
- W2898092602 creator A5044795397 @default.
- W2898092602 creator A5052608673 @default.
- W2898092602 creator A5063300526 @default.
- W2898092602 creator A5075149323 @default.
- W2898092602 creator A5075877134 @default.
- W2898092602 creator A5085807326 @default.
- W2898092602 date "2018-10-01" @default.
- W2898092602 modified "2023-09-30" @default.
- W2898092602 title "P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy" @default.
- W2898092602 doi "https://doi.org/10.1016/j.jtho.2018.08.1553" @default.
- W2898092602 hasPublicationYear "2018" @default.
- W2898092602 type Work @default.
- W2898092602 sameAs 2898092602 @default.
- W2898092602 citedByCount "6" @default.
- W2898092602 countsByYear W28980926022020 @default.
- W2898092602 countsByYear W28980926022021 @default.
- W2898092602 countsByYear W28980926022022 @default.
- W2898092602 countsByYear W28980926022023 @default.
- W2898092602 crossrefType "journal-article" @default.
- W2898092602 hasAuthorship W2898092602A5004849412 @default.
- W2898092602 hasAuthorship W2898092602A5026731588 @default.
- W2898092602 hasAuthorship W2898092602A5032753570 @default.
- W2898092602 hasAuthorship W2898092602A5036091074 @default.
- W2898092602 hasAuthorship W2898092602A5037979055 @default.
- W2898092602 hasAuthorship W2898092602A5044795397 @default.
- W2898092602 hasAuthorship W2898092602A5052608673 @default.
- W2898092602 hasAuthorship W2898092602A5063300526 @default.
- W2898092602 hasAuthorship W2898092602A5075149323 @default.
- W2898092602 hasAuthorship W2898092602A5075877134 @default.
- W2898092602 hasAuthorship W2898092602A5085807326 @default.
- W2898092602 hasBestOaLocation W28980926021 @default.
- W2898092602 hasConcept C121608353 @default.
- W2898092602 hasConcept C126322002 @default.
- W2898092602 hasConcept C143998085 @default.
- W2898092602 hasConcept C146357865 @default.
- W2898092602 hasConcept C151730666 @default.
- W2898092602 hasConcept C2775949291 @default.
- W2898092602 hasConcept C2776256026 @default.
- W2898092602 hasConcept C2776694085 @default.
- W2898092602 hasConcept C2777701055 @default.
- W2898092602 hasConcept C2778292576 @default.
- W2898092602 hasConcept C2779177807 @default.
- W2898092602 hasConcept C2780057760 @default.
- W2898092602 hasConcept C530470458 @default.
- W2898092602 hasConcept C71924100 @default.
- W2898092602 hasConcept C81729549 @default.
- W2898092602 hasConcept C86803240 @default.
- W2898092602 hasConceptScore W2898092602C121608353 @default.
- W2898092602 hasConceptScore W2898092602C126322002 @default.
- W2898092602 hasConceptScore W2898092602C143998085 @default.
- W2898092602 hasConceptScore W2898092602C146357865 @default.
- W2898092602 hasConceptScore W2898092602C151730666 @default.
- W2898092602 hasConceptScore W2898092602C2775949291 @default.
- W2898092602 hasConceptScore W2898092602C2776256026 @default.
- W2898092602 hasConceptScore W2898092602C2776694085 @default.
- W2898092602 hasConceptScore W2898092602C2777701055 @default.
- W2898092602 hasConceptScore W2898092602C2778292576 @default.
- W2898092602 hasConceptScore W2898092602C2779177807 @default.
- W2898092602 hasConceptScore W2898092602C2780057760 @default.
- W2898092602 hasConceptScore W2898092602C530470458 @default.
- W2898092602 hasConceptScore W2898092602C71924100 @default.
- W2898092602 hasConceptScore W2898092602C81729549 @default.
- W2898092602 hasConceptScore W2898092602C86803240 @default.
- W2898092602 hasIssue "10" @default.
- W2898092602 hasLocation W28980926021 @default.
- W2898092602 hasOpenAccess W2898092602 @default.
- W2898092602 hasPrimaryLocation W28980926021 @default.
- W2898092602 hasRelatedWork W167319750 @default.
- W2898092602 hasRelatedWork W1987468340 @default.
- W2898092602 hasRelatedWork W2055244776 @default.
- W2898092602 hasRelatedWork W2348529436 @default.
- W2898092602 hasRelatedWork W2413020017 @default.
- W2898092602 hasRelatedWork W2569676502 @default.
- W2898092602 hasRelatedWork W2948845624 @default.
- W2898092602 hasRelatedWork W4231596293 @default.
- W2898092602 hasRelatedWork W4311334540 @default.
- W2898092602 hasRelatedWork W4319224783 @default.
- W2898092602 hasVolume "13" @default.
- W2898092602 isParatext "false" @default.
- W2898092602 isRetracted "false" @default.
- W2898092602 magId "2898092602" @default.
- W2898092602 workType "article" @default.